Allergan (AGN) announced that the FDA has approved the use of its NAMZARIC (memantine hydrochloride and donepezil hydrochloride) extended-release capsules in patients with moderate-to-severe Alzheimer's disease (AD) who are currently stabilized on Aricept (donepezil hydrochloride), allowing them to directly start combination therapy. NAMZARIC was approved in the U.S. in December 2014 for moderate-to-severe AD patients who are currently taking memantine HCl and donepezil HCl.